Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001469 · ClinicalTrials.gov registry record
Genetic Analysis of Hereditary Prostate Cancer
A clinical trial, sponsored by National Human Genome Research Institute (NHGRI).
- Completed
- Registry status
- 7,776
- Enrollment target
NCT00001469 is a clinical trial that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 7,776 participants.
The verdict
NCT00001469 has completed, sponsored by National Human Genome Research Institute (NHGRI).
- COMPLETED
- Registry status
- 7,776 participants
- Enrollment target
Study Summary
Molecular approaches to the understanding of human neoplastic disease have revealed that multiple genetic alterations are an essential component of tumorigenesis. Both germline and somatic genetic alterations can be involved in the malignant transformation of normal cells. Identification of the genes involved in neoplastic transformation has been approached through the molecular analysis of sporadic cancers and the genetic study of families with an inherited predisposition for cancer. The interplay of these two approaches has led to the characterization of genes such as the retinoblastoma (Rb) gene, the p53 gene and the adenomatous polyposis coli (APC) gene that are all involved in the development of both hereditary and non-hereditary forms of cancer. Inherited mutations in such genes predispose affected families to hereditary cancer syndromes, affording an opportunity to identify genetic lesions that also cause the more common sporadic cancers. Prostate cancer (PRCA) is the most common cancer diagnosed (1999 estimate 179,300 cases) and the second leading cause of cancer mortality (1999 estimate 37,000 deaths) in men in the United States. Family history is the single strongest risk factor currently known for prostate cancer. This raises the possibility that heritable genetic factors may be involved in the development of this disease in a subset of men. The genetic contribution to diseases of complex origin such as cancer is often most salient in families of early onset cases. Therefore, prostate cancer inheritance following a simple Mendelian pattern may be identified in the families of probands with early-onset cases. Common susceptibility alleles of small effect may be detectable in families with later-onsent and/or less strong family history of PRCA or in case-control data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,776 participants |
| Start Date | 1995-01-01 |
| Est. Completion | 2009-07-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001469
The ClinicalTrials.gov registry entry for NCT00001469 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7,776 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001469 about?
NCT00001469 is a clinical study titled "Genetic Analysis of Hereditary Prostate Cancer". Molecular approaches to the understanding of human neoplastic disease have revealed that multiple genetic alterations are an essential component of tumorigenesis. Both germline and somatic genetic alterations can be involved in the malignant transformation of normal cells. Identification of the gene...
What is the current status of trial NCT00001469?
This trial is currently completed. The enrollment target is 7,776 participants. The study started on 1995-01-01. Estimated completion is 2009-07-17.
Who is sponsoring clinical trial NCT00001469?
This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.